炎症性肠病由静脉转为皮下维得利珠单抗维持治疗的真实世界经验
这项前瞻性队列研究纳入82例克罗恩病和53例溃疡性结肠炎患者,将从静脉维得利珠单抗维持治疗转为皮下制剂,评估有效性、安全性和药代动力学。中位临床和生化疾病活动度保持稳定,中位血清维得利珠单抗浓度从转换时19 μg/ml升至转换后12周31 μg/ml(p < 0.005)。但9%患者因不良事件或恐针转回静脉制剂。
要点
- 中位临床和生化疾病活动度在转换后保持稳定
- 中位血清维得利珠单抗浓度从转换时19 μg/ml升至12周31 μg/ml(p < 0.005)
- 9%患者因不良事件或恐针转回静脉维得利珠单抗
核心结论
- 对于克罗恩病或溃疡性结肠炎患者,从静脉转为皮下维得利珠单抗维持治疗是有效的
- 但9%患者因不良事件或恐针转回静脉维得利珠单抗
研究设计与样本
- 前瞻性队列研究,纳入82例克罗恩病患者和53例溃疡性结肠炎患者,均已接受至少4个月静脉维得利珠单抗治疗
- 患者转为皮下维得利珠单抗维持治疗,研究至停用皮下制剂的时间、不良事件、临床和生化结局变化及基线、12周和24周的维得利珠单抗浓度
主要发现
- 克罗恩病患者中11例(13.4%)停用皮下维得利珠单抗,中位停药时间为18周(IQR 8-22);溃疡性结肠炎患者中5例(9.4%)停药,中位停药时间为6周(IQR 5-10)
- 克罗恩病患者中4例因失去应答换用其他药物,9例因不良事件转回静脉维得利珠单抗,3例因恐针转回
- 常见不良事件为注射部位反应(n=15)和头痛(n=6)
- 转换后中位临床和生化疾病活动度保持稳定
- 中位血清维得利珠单抗浓度从转换时19 μg/ml升至转换后12周31 μg/ml(p < 0.005)
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Subcutaneous (SC) vedolizumab is effective in inflammatory bowel diseases (IBD) when administered after induction with two infusions. AIM: To assess the effectiveness, safety and pharmacokinetics of a switch from intravenous (IV) to SC maintenance vedolizumab in patients with IBD METHODS: In this prospective cohort study, patients with IBD who had ≥4 months IV vedolizumab were switched to SC vedolizumab. We studied the time to discontinuation of SC vedolizumab, adverse events (AEs), changes in clinical and biochemical outcomes and vedolizumab concentrations at baseline, and weeks 12 and 24. RESULTS: We included 82 patients with Crohn's disease (CD) and 53 with ulcerative colitis (UC). Eleven (13.4%) patients with CD and five (9.4%) with UC discontinued SC vedolizumab after a median of 18 (IQR 8-22) and 6 weeks (IQR 5-10), respectively. Four patients with CD switched to a different drug due to loss of response, nine switched back to IV vedolizumab due to adverse events, and three due to needle fear. Common AEs were injection site reactions (n = 15) and headache (n = 6). Median clinical and biochemical disease activity remained stable after the switch. Median serum vedolizumab concentrations increased from 19 μg/ml at the time of the switch to 31 μg/ml 12 weeks after the switch (p < 0.005). CONCLUSIONS: Switching from IV to SC vedolizumab maintenance treatment is effective in patients with CD or UC. However, 9% of patients were switched back to IV vedolizumab due to adverse events or fear of needles.
引用
- Volkers A, Straatmijer T, Duijvestein M, et al. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther. 2022. PMID: 35869807. doi:10.1111/apt.17153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。